Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents.

LAPC LPC LPC/LAPC early-stage prostate cancer localised prostate cancer locally advanced prostate cancer

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
13 May 2024
Historique:
received: 15 12 2023
revised: 21 03 2024
accepted: 26 03 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 14 5 2024
Statut: aheadofprint

Résumé

Understanding stakeholders' perception of cure in prostate cancer (PC) is essential to preparing for effective communication about emerging treatments with curative intent. This study used artificial intelligence (AI) for landscape review and linguistic analysis of definition, context and value of cure among stakeholders in PC. Subject-matter experts (SMEs) selected cure-related key words using Elicit, a semantic literature search engine, and extracted hits containing the key words from Medline, Sermo and Overton, representing academic researchers, health care providers (HCPs) and policymakers, respectively. NetBase Quid, a social media analytics and natural language processing tool, was used to carry out key word searches in social media (representing the general public). NetBase Quid analysed linguistics of key word-specific hit sets for key word count, geolocation and sentiments. SMEs qualitatively summarised key word-specific insights. Contextual terms frequently occurring with key words were identified and quantified. SMEs identified seven key words applicable to PC (number of acquired hits) across four platforms: Cure (12429), Survivor (6063), Remission (1904), Survivorship (1179), Curative intent (432), No evidence of disease (381) and Complete remission (83). Most commonly used key words were Cure by the general public and HCPs (11815 and 224 hits), Survivorship by academic researchers and Survivor by policymakers (378 hits each). All stakeholders discussed Cure and cure-related key words primarily in early-stage PC and associated them with positive sentiments. All stakeholders defined cure differently but communicated about it in relation to disease measurements (e.g. prostate-specific antigen) or surgery. Stakeholders preferred different terms when discussing cure in PC: Cure (academic researchers), Cure rates (HCPs), Potential cure and Survivor/Survivorship (policymakers) and Cure and Survivor (general public). This human-led, AI-assisted large-scale qualitative language-based research revealed that cure was commonly discussed by academic researchers, HCPs, policymakers and the general public, especially in early-stage PC. Stakeholders defined and contextualised cure in their communications differently and associated it with positive value.

Sections du résumé

BACKGROUND BACKGROUND
Understanding stakeholders' perception of cure in prostate cancer (PC) is essential to preparing for effective communication about emerging treatments with curative intent. This study used artificial intelligence (AI) for landscape review and linguistic analysis of definition, context and value of cure among stakeholders in PC.
MATERIALS AND METHODS METHODS
Subject-matter experts (SMEs) selected cure-related key words using Elicit, a semantic literature search engine, and extracted hits containing the key words from Medline, Sermo and Overton, representing academic researchers, health care providers (HCPs) and policymakers, respectively. NetBase Quid, a social media analytics and natural language processing tool, was used to carry out key word searches in social media (representing the general public). NetBase Quid analysed linguistics of key word-specific hit sets for key word count, geolocation and sentiments. SMEs qualitatively summarised key word-specific insights. Contextual terms frequently occurring with key words were identified and quantified.
RESULTS RESULTS
SMEs identified seven key words applicable to PC (number of acquired hits) across four platforms: Cure (12429), Survivor (6063), Remission (1904), Survivorship (1179), Curative intent (432), No evidence of disease (381) and Complete remission (83). Most commonly used key words were Cure by the general public and HCPs (11815 and 224 hits), Survivorship by academic researchers and Survivor by policymakers (378 hits each). All stakeholders discussed Cure and cure-related key words primarily in early-stage PC and associated them with positive sentiments. All stakeholders defined cure differently but communicated about it in relation to disease measurements (e.g. prostate-specific antigen) or surgery. Stakeholders preferred different terms when discussing cure in PC: Cure (academic researchers), Cure rates (HCPs), Potential cure and Survivor/Survivorship (policymakers) and Cure and Survivor (general public).
CONCLUSION CONCLUSIONS
This human-led, AI-assisted large-scale qualitative language-based research revealed that cure was commonly discussed by academic researchers, HCPs, policymakers and the general public, especially in early-stage PC. Stakeholders defined and contextualised cure in their communications differently and associated it with positive value.

Identifiants

pubmed: 38744101
pii: S2059-7029(24)00775-0
doi: 10.1016/j.esmoop.2024.103007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103007

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

E Efstathiou (E)

Houston Methodist, Houston, Texas, USA. Electronic address: eefstathiou@houstonmethodist.org.

A Merseburger (A)

University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

A Liew (A)

Oxford PharmaGenesis Group Pty Ltd, Melbourne, Australia.

K Kurtyka (K)

Oxford PharmaGenesis Inc, Newtown, Pennsylvania, USA.

O Panda (O)

Oxford PharmaGenesis Inc, Newtown, Pennsylvania, USA.

D Dalechek (D)

Oxford PharmaGenesis Inc, Newtown, Pennsylvania, USA.

A C S Heerdegen (ACS)

Janssen Global Commercial Strategy Organization, Raritan, New Jersey, USA.

R Jain (R)

Janssen Global Commercial Strategy Organization, Raritan, New Jersey, USA.

F De Solda (F)

Janssen Global Commercial Strategy Organization, Raritan, New Jersey, USA.

S A McCarthy (SA)

Janssen Research & Development, Raritan, New Jersey, USA.

S D Brookman-May (SD)

Janssen Research & Development, Spring House, Pennsylvania, USA; Ludwig-Maximilians-University, Munich, Germany.

S D Mundle (SD)

Janssen Research & Development, Raritan, New Jersey, USA.

W Yu Ko (W)

University of British Columbia Men's Health Research Program, Vancouver, British Columbia, Canada.

L-M Krabbe (LM)

Vivantes Hospital Network for Health, Berlin, Germany.

Classifications MeSH